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Tom van der Poll, MD, PhD1,4 and W. Joost Wiersinga, MD, PhD1,4
OBJECTIVES: Broad-spectrum antibiotics disrupt the intestinal microbiota. The microbiota is essential for physiological
processes, such as the development of the gut immune system. Recent murine data suggest that the intestinal microbiota also
modulates systemic innate immune responses; however, evidence in humans is lacking.
METHODS: Twelve healthy young men were given oral broad-spectrum antibiotics (ciprofloxacin 500 mg bid, vancomycin 500 mg
tid and metronidazole 500 mg tid) for 7 days. At baseline, 1 day, and 6 weeks after antibiotics, blood and feces were sampled. Whole
blood and isolated mononuclear cells were stimulated with selected Toll-like receptor agonists and heat-killed bacteria. Microbiota
diversity and composition was determined using bacterial 16S rDNA sequencing.
RESULTS: One day after the antibiotic course, microbial diversity was significantly lower compared with baseline. After antibiotic
therapy, systemic mononuclear cells produced lower levels of tumor necrosis factor (TNF)-α after ex vivo stimulation with
lipopolysaccharide (LPS). This diminished capacity to produce TNF-αwas restored 6 weeks after cessation of antibiotic therapy. In
whole blood, a reduced capacity to release interleukin (IL)-1β and IL-6 was observed after LPS stimulation. Antibiotic treatment did
not impact on differential leukocyte counts, phagocytosis, and cell surface markers of neutrophils and monocytes.
CONCLUSIONS: In this proof-of-principle study of healthy subjects, microbiota disruption by broad-spectrum antibiotics
is reversibly associated with decreased systemic cellular responsiveness towards LPS. The implications of these findings in a
clinical setting remain to be determined.
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INTRODUCTION
No less than 842 antibiotic courses per 1000 Americans were
prescribed in 2011.1 The effect of broad-spectrumantibiotics on
the gut microbiota is profound: within days a marked loss of
diversity and shift in community composition is seen.2 Given the
increasing knowledge on the physiological functions of the
intestinal microbiota, which some now even refer to as an
“organ in an organ”, the use of antibiotics may have adverse
consequences that we are currently unaware of. Themicrobiota
has a fundamental role inmetabolism and in the development of
the immune system.3,4 The important contribution of a well-
balanced intestinal microbiota in host defense against infec-
tions, e.g., by colonization resistance, is underscored by
the high effectiveness of fecal microbiota transplantation as
treatment for recurrent Clostridium difficile infections and
potentially other diseases, such as ulcerative colitis.5,6
Recent preclinical work has suggested that themicrobiota also
acts as a modulator of systemic immunity.7–11 In mice, microbial
products such as peptidoglycan were shown to prime the innate
immune system, thereby enhancing responses against invading
pathogens. A decreased production of neutrophils by the bone
marrowwas observed inmice that were treated with antibiotics or
thatwereborn germ-free.8,9,12Accordingly, host defensesagainst
Streptococcus pneumoniae,Klebsiella pneumoniae,Escherichia
coli, Staphylococcus aureus, and Listeria are less effective in
these mice7–10,13—mostly attributed to decreased phagocytosis
and killing by neutrophils and alveolar macrophages.7,10,13
However, evidence of the intestinal microbiota as modulator
of systemic immunity in humans is lacking. We hypothesized
that microbiota disruption by antibiotics has adverse conse-
quences on the systemic cellular responsiveness toward
danger signals such as microbe-associated molecular patterns
from pathogens. As such, the use of antibiotics may lead to
immunosuppression, as seen in patients with trauma, burns, or
sepsis.14 In this proof-of-principle study, we investigated the
effect of gut microbiota disruption by broad-spectrum antibiotics
on systemic innate immune responses in healthy subjects.
METHODS
Subjects. Twelve healthy Caucasian male subjects were
given oral antibiotics (ciprofloxacin 500 mg bid, vancomycin
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500 mg tid, and metronidazole 500 mg tid) for 7 days. Before,
1 day after antibiotics, and 6 weeks later, blood and feces
were sampled (Figure 1a). Ethical approval was received
from the Medical Ethics Committee, Academic Medical
Center. All subjects gave written informed consent
(Netherlands Trial Registry NTR3629). Prior to participation,
healthy subjects underwent a medical screening, including
medical history, physical examination, and hematological and
biochemical screening. Participants did not smoke or use any
medication. Subjects were excluded if they had used any kind
of antibiotics within 1 year, if they had an abnormal bowel
frequency (o3 bowel movements per week or 43 per day),
or travel planned during the study period. Subjects did not
use any nutritional supplements or probiotics and did not
follow a vegetarian diet nor were they given dietary
instructions. Mean age was 22.2 years (s.d. 2.5) and mean
body mass index 22.6 kg/m2 (s.d. 2.2).
Stimulation assays. Whole blood and purified peripheral
blood mononuclear cells (PBMCs) were used for stimu-
lation assays. Venous blood was drawn into 10 ml heparin
vacutainers (BD Biosciences, Mountain View, CA). For PBMC
isolation, blood was diluted 1:1 in phosphate-buffered saline,
and fractions were separated by Ficoll density gradient
centrifugation (Ficoll-Paque Plus; GE Healthcare, Zeist, The
Netherlands).15 After isolation of the PBMC fraction, the cell
suspension was incubated with sterile erythrocyte lysis buffer
(155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA, pH 7.4) for
15min on ice. Cells were washed twice with phosphate-
buffered saline and resuspended in RPMI 1640 medium
(Life Technologies, Invitrogen, Breda, The Netherlands). The
cell number was adjusted using a particle counter (Beckmann
Coulter, Woerden, The Netherlands).
Whole blood and PBMCs were mixed in 96-well plates with
an equal volume of either plain RPMI or RPMI containing Toll-
like receptor (TLR) ligands or heat-killed bacteria.16 Final
concentration of PBMCs was 2.5 × 106/ml. Whole blood was
stimulated for 24 h with final concentrations of lipopolysac-
charide (LPS) 10 ng/ml (E. coli 0111:B4, ultrapure; Invivo-
Gen), PAM3CSK4 1 μg/ml (InvivoGen, San Diego, CA),
Flagellin 0.1 μg/ml (S. typhymurium, ultrapure; InvivoGen),
heat-killed S. pneumoniae (serotype 2, D39), K. pneumoniae
(serotype 2), or B. pseudomallei (clinical isolate 1026b). All
bacteria were grown until mid-log phase, washed with saline,
heat killed at 70 °C for 30 min, and used at an end
concentration of 1 × 10E6 colony-forming units/ml. Addition-
ally, PBMCs were stimulated for 4 h with LPS 100 ng/ml in 24-
well plates. All stimuli were prediluted in RPMI, aliquoted, and
stored at −20 °C. After incubation at 37 °C in 5% CO2,
supernatant was obtained by centrifugation and stored at
−20 °C. Cytokine production was measured by cytometric
bead array (Human Inflammation Kit, BDBioscience,
San Jose, CA) using a FACS Calibur (BD Biosciences).
Granulocyte colony-stimulating factor was measured in
plasma by enzyme-linked immunosorbent assay (RnD
Systems, Minneapolis, MN).
Microbiota analysis. Full microbiota analyses are des-
cribed in Supplementary Material online. Briefly, fresh stool
samples were stored at − 20 °C and transferred to −80 °C
within 24 h. Bacterial DNA was extracted using a bead-
beating protocol and 16S rDNA was amplified with primers
27F-DegS and 338R as described before.17 Illumina Miseq
sequencing was performed (Illumina, San Diego, CA, USA),
followed by analysis with the QIIME software package
(available at http://qiime.sourceforge.net/) as described.18,19
All samples were processed and sequenced in one run.
Unconstrained principal component analysis was performed
using the Canoco 5 software (Biometris, Wageningen, The
Netherlands).
Statistics. Normal distribution of each data set was evalu-
ated using a D’Agostino and Pearson normality test. If
normally distributed, comparisons between groups were
made using paired t-tests and data are represented as
mean± s.d.; if not normally distributed, data were analyzed
using Wilcoxon’s signed-rank test and data are represented
as median± interquartile range (all using GraphPad Prism 5,
GraphPad Software, San Diego, CA). Values of Po0.05 were
considered to represent statistically significant differences.
Figure 1 (a) Study design. (b) Gut microbiota diversity (represented as Shannon Index) based on the sequence data of bacterial 16S rRNA genes. Results are presented as
box- and whisker plots showing the smallest observation, lower quartile, median, upper quartile and largest observation; P-values are calculated between time points as indicated
by lines. ***Po0.001. (c) Principal component analysis (unconstrained) of fecal microbial communities. On the horizontal axis is Principal Component 1 and on the vertical axis
Principal Component 2 with their corresponding percentages of explained variance. White bars or circles: day 0, black: day 8, gray: week 7.
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Analysis of fecal microbiota composition was performed with
the non-linear mixed-effects package in R. Differences
between samples of day 0 vs. day 8 and day 0 vs. week 7
were computed using a linear mixed model, and P values were
corrected for multiple comparisons by the q-value package.
As the present study is explorative in nature, no formal
power calculation was performed. A subject number of 12
would, however, be sufficient to provide 80% power to detect
differences of 20%, assuming a s.d. of 20% with α= 0.05.
Further methods on phagocytosis assays and cell surface
markers are available in Supplementary Material online.
RESULTS
Intestinal microbiota disruption by antibiotics. Adminis-
tration of broad-spectrum antibiotics disrupted the gut
microbiota in all subjects, lowering median Shannon diver-
sity from 3.4 to 1.5 (Figure 1b) with 49 bacterial groups
differentially present on day 8 compared with before treat-
ment (see Supplementary Figure S1 online). A strong relative
increase in bacteria of the genus Streptococcus was the most
striking change in all subjects. In two subjects, a large
proportion of bacteria consisted of Streptophyta; likewise,
Lactobacilli were significantly increased in two other subjects.
Genera that had disappeared compared with before
treatment included Prevotella, Megamonas, Lachnospira-
ceae, and Bacteroides. Six weeks later, the intestinal
bacterial communities had almost returned to their initial
diversity (median Shannon Index 2.9, statistically significant
compared with both days 0 and 8) but remained different from
before treatment as reflected in an unconstrained principal
component analysis (Figure 1c). Apart from some gastro-
intestinal discomfort, none of the subjects experienced any
clinically relevant consequences such as C. difficile infection.
Cytokine production. Strikingly, microbiota disruption was
associated with lower interleukin (IL)-1β and IL-6 production
upon 24-h stimulation of whole blood with LPS but not
tumor necrosis factor (TNF)-α production (Figure 2a–c). In
line, stimulation with Gram-negative K. pneumoniae and
B. pseudomallei, but not Gram-positive S. pneumoniae or
TLR2/5 agonists, resulted in a trend toward diminished IL-1β
and IL-6 release (see Supplementary Figure S2 online).
Isolated PBMCs stimulated with LPS showed a similar
reduced capacity to release the early proinflammatory
cytokine TNF-α, but not IL-6 and IL-1β (Figure 2d–f). These
defects were restored 6 weeks after antibiotics.
Phagocytosis. Given the findings in mice that the gut
microbiota affects the phagocytic function of bone marrow–
derived neutrophils,7 we also performed phagocytosis assays
Figure 2 (a–c) Tumor necrosis factor (TNF)-α, interleukin (IL)-6, and IL-1β levels in supernatant after stimulation of whole blood with lipopolysaccharide (LPS) 10 ng/ml for
24 h; (d–f) TNF-α, IL-6, and IL-1β levels in supernatant after stimulation of isolated peripheral blood mononuclear cells with 100 ng/ml LPS for 4 h. White bars represent day 0,
black bars day 8, and gray bars week 7. Results are represented as mean± s.d. (a–d) or median± interquartile range (e and f); P-values are calculated between groups as
indicated by lines. *Po0.05, NS, not statistically significant.
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with whole blood. However, treatment with broad-spectrum
antibiotics did not affect the capacity of neutrophils and
monocytes in whole blood to phagocytose heat-killed
S. pneumoniae or K. pneumoniae (see Supplementary
Figure S3 online). As granulopoiesis is influenced by the
microbiota in mice as well,8,9 we looked at total blood cell
counts and differential white blood cell counts, but these were
similar before and after antibiotics (data not shown).
Granulocyte colony-stimulating factor in plasma was below
detection (data not shown).
Cell surface markers. Finally, we used fluorescence-
activated cell sorting analysis to investigate whether disrup-
tion of the gut microbiota affects the activation status of
unstimulated monocytes and neutrophils (reflected by their
expression of CD11b, CD62L, and HLA-DR), their expression
levels of TLRs (TLR2, TLR4, and TLR5), and the modulating
protein-triggering receptor expressed on myeloid cells-1.
None of these were changed after microbiota disruption
(data not shown).
DISCUSSION
Our findings suggest that gut microbiota disruption by
broad-spectrum antibiotics influences TNF-α production by
mononuclear cells upon stimulation with LPS. Nonetheless,
the overall effect of microbiota disruption on measured sys-
temic immune responses was limited. To our knowledge, this
intervention study is the first to investigate the interplay
between intestinal microbiota and the systemic innate immune
system in healthy humans. Up to now, most human studies in
the research field of microbiota and innate immune system are
associative. The likelihood of microbiota disturbance has, for
example, been positively correlated with the risk of subse-
quent severe sepsis in a cohort of 10,996 patients.20 Studies
in critically ill patients are limited to descriptive cohort
studies, mostly associating higher bacterial diversity with
better outcome.21–24
Mouse studies have reported several mechanisms by which
antibiotic microbiota disruption may negatively affect host
responses against invading pathogens. Our results support
some, but not all, of the postulated hypotheses. First, murine
studies have suggested that granulopoiesis is an important
aspect of microbiota-related protection from infection.8,9,12 We
did not find any differences in neutrophil numbers in peri-
pheral blood after antibiotic treatment, compared with before.
Second, a difference in phagocytic or killing functions of
neutrophils has been reported in antibiotic-treated mice.7 We
tested the phagocytic capacities of neutrophils in whole blood
but again did not find any differences. Finally, cytokine
production has been reported to be affected by the microbial
status of mice.8,10 Our results corroborate these studies, as
production of TNF-α by mononuclear cells upon LPS stimula-
tion was significantly lower after the antibiotic course. To a
lesser extent, IL-1β and IL-6 production by whole blood upon
Gram-negative stimulation was affected as well.
Several factors could explain the differences between the
present study and previous mouse studies. Some of the
reported experiments were performed in neonatal mice; the
bone marrow of healthy adults may be much less sensitive to
microbial signals than that of children. Also, redundancy in the
innate immune system may compensate for any small deficit
caused by microbiota disruption. Finally, humans are much
more diverse than mice in their genetic makeup, environment,
andmicrobiota, which couldmake it more difficult to detect any
small changes in immune effector functions. Still, this study
was designed to be as controlled as possible.
This proof-of-concept study has several limitations. First, it
is not possible to associate the observed effects with specific
antibiotics or bacterial taxa owing to the broad-spectrum
antibiotic regimen, which was chosen to achieve the largest
possible effect on the intestinal microbiota. Second, a 24-h
antibiotic washout period was included to avoid direct effects
of antibiotics present in blood on the performed tests. We
cannot exclude that partial recovery of the microbiota and
immune system has taken place during this interval. Further-
more, similar to most human microbiota studies, we have
focused on bacteria only as they comprise the vast majority
of the intestinal microbiota. Fungi, viruses, and archaea may,
however, have a significant role when bacteria are eradicated
by antibiotics. Finally, interindividual differences in microbiota
composition may be an important factor, although numbers of
genes for bacterial metabolic pathways are very similar among
healthy people, even if those genes are coming from different
kinds of bacteria.25 Still, it is important to keep in mind that
these results may not translate to people with a different diet,
sex, age, or genetic background—or to patients, where
comorbidities and medications come into play.
TNF-α is of major importance in the host defense against
invading pathogens, as is evident from the occurrence of severe
infections in patients who receive TNF-α blocking agents.26
Decreased TNF-α production caused by antibiotic microbiota
disruption may therefore have detrimental effects in, for
example, critically ill patients, in whom immunosuppression is
a common phenomenon.14 These effects could be more
pronounced in patients with any underlying immune-mediated
diseases, but further research is needed to further explore this.
For example, the selection of healthy donors for fecal microbiota
transplantation for immune-related diseases such as inflam-
matory bowel disease and autoimmune diseases could be
improved through further knowledge on this subject.
If our results are to be reproduced, future research should
focus on the underlyingmechanisms. It will be of importance to
clarify which bacteria or which bacterial components of the
microbiota are key players in these immunostimulatory
processes. Ultimately, potential therapeutic strategies that
target the microbiota in order to boost the immune system
during systemic illness may be explored. Of interest, a first
patient with therapy-resistant sepsis and diarrhea has recently
been treated with fecal microbiota transplantation.27
In conclusion, these data suggest the existence of systemic
immunomodulation by the microbiota in humans and highlight
potential adverse consequences of microbiota disruption
by broad-spectrum antibiotics on TNF-α-related immune
defenses to infection.
Translational impact. Antibiotics could have unknown
adverse consequences by affecting systemic innate immune
defenses via microbiota disruption. Further research should
elucidate the mechanisms behind this finding.
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✓ Antibiotics are among themost often prescribedmedications.
✓ The intestinal microbiota is disrupted by broad-spectrum
antibiotics.
✓ Inmice, a well-balancedmicrobiota appears to stimulate the
systemic innate immune system.
WHAT IS NEW HERE
✓ In healthy humans, antibiotic microbiota disruption is
reversibly associated with decreased TNF-α production by
mononuclear cells.
✓ Broad-spectrum antibiotic treatment did not impact on
differential leukocyte counts, phagocytosis, and cell surface
markers of neutrophils and monocytes.
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